Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard (NYSE:BCR) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at C.R. Bard and see what CAPS investors are saying about the stock right now.

C.R. Bard facts

Headquarters (founded)

Murray Hill, N.J. (1907)

Market Cap

$8.5 billion

Industry

Health care equipment

Trailing-12-Month Revenue

$3.0 billion

Management

Chairman/CEO Timothy Ring
President/COO John Weiland

Return on Equity (average, past 3 years)

22.2%

Cash/Debt

$809.1 million / $1.3 billion

Dividend Yield

0.8%

Competitors

Covidien
Becton Dickinson
Boston Scientific

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 274 members who have rated C.R. Bard believe the stock will outperform the S&P 500 going forward.

A couple of weeks ago, one of those Fools, All-Star DrGoldin, succinctly summed up the C.R. Bard bull case for our community: "They're profitable. They're CONSISTENTLY profitable. They're in a sector that can only improve. The price is reasonable. What's not to like?"

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson and Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.